Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Fig. 1

Overexpression of the unmutated RRAS2 leads to a B cell leukemia in mice. a & b Genomic alterations in the KRAS and RRAS2 genes according to cBioportal for cancer genomics (http://www.cbioportal.org). Data represent a combined study of 78,278 patients/81072 samples. The X-axis represents alteration frequency of the gene (colors represent the alteration type). The Y-axis represents different cancer types. c Relative mRNA expression of RRAS2 in different cancers. Data are represented in log2 scale and were obtained from the Pan-Cancer Analysis of Whole Genomes (PCAWG). d Representative images of the relative sizes of spleens from 12 month-old control and Sox2-Cre + mice. e Quantification of the total number of B cells per spleen of 6 month-old control and Sox2-Cre + mice. Data shown correspond to triplicate measurements of one control and three Sox2-Cre mice. Unpaired t-test with Welch’s correction. f Hematoxylin and eosin images of the spleen structure in an 8-month old control mouse and in 4-, 8- and 12-month-old Sox2-Cre + mice. g Two-parameter flow cytometry of the expression of CD21 and CD23, and IgD and IgM, respectively, in B cells in spleens of 8 month-old control and Sox2Cre + mice h Left, two-parameter flow cytometry of the expression of CD5 and IgM in B cells of the blood of 8 month-old control and Sox2-Cre + mice. i, quantification of the number of CD5 + IgM+ B cells in the blood of 40 wk-old control and Sox2-Cre + mice. Data shown correspond to duplicate measurements of four control and six Sox2-Cre mice. Unpaired t-test with Welch’s correction. In all figures, control mice refer to Rosa26-RRAS2fl/fl without Cre recombinase

Back to article page